Indivior Pharmaceuticals 過去の業績
過去 基準チェック /46
Indivior Pharmaceuticalsは5.4%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで13.5%毎年増加している。売上は成長しており、年平均11.3%の割合である。
主要情報
5.44%
収益成長率
9.90%
EPS成長率
| Pharmaceuticals 業界の成長 | 5.95% |
| 収益成長率 | 11.35% |
| 株主資本利益率 | n/a |
| ネット・マージン | 26.75% |
| 前回の決算情報 | 30 Jun 2026 |
最近の業績更新
Recent updates
ナラティブ更新 • Aug 05
INDV: Merger And Special Dividend Will Support Turnaround Repricing
Analysts have raised their price target on Indivior Pharmaceuticals stock from $50 to $53, citing recent Q2 results, updated guidance, the planned merger with Supernus, and expectations for stronger revenue growth, slightly higher profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts see the recent moves around Indivior Pharmaceuticals as a sign that the stock is gaining traction with the market.
ナラティブ更新 • Jul 10
INDV: Turnaround Plan And Index Additions Will Drive Earnings Momentum
Analysts lifted their fair value estimate for Indivior Pharmaceuticals stock from about $37.86 to roughly $50.83, citing expectations for stronger revenue growth, a higher future P/E, and an improved earnings trajectory supported by Indivior's turnaround plan, which is focused on accelerating Sublocade and profitability. What’s in the News for Indivior Pharmaceuticals Indivior Pharmaceuticals was added to the Russell 2000 Defensive, Russell 2000 Growth-Defensive, and Russell 2000 Value-Defensive Indexes on 27 June 2026, broadening its presence across multiple benchmarks and potentially influencing index-tracking fund activity.ナラティブ更新 • Jun 26
INDV: Raised Guidance And Buybacks Will Support A Turnaround Repricing
Analysts have lifted their price target for Indivior Pharmaceuticals from $50 to about $58, citing expectations for improved revenue growth, a slightly higher discount rate, adjusted profit margins, and a modestly higher future P/E multiple. These expectations are supported by recent research highlighting the company's turnaround plan and its focus on accelerating Sublocade and profitability.分析記事 • Jun 18
Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds
Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics. See our latest analysis for Indivior Pharmaceuticals. The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%,...Seeking Alpha • Jun 09
Indivior: A Stronger Business Than When I First Covered It
Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking AlphaSeeking Alpha • Apr 28
Indivior: Trying To Break Addiction
Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 13
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking AlphaSeeking Alpha • Jul 26
Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback
Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking Alpha収支内訳
収支内訳
Indivior Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 26 | 1,331 | 356 | 527 | 51 |
| 31 Mar 26 | 1,290 | 252 | 567 | 67 |
| 31 Dec 25 | 1,239 | 210 | 578 | 80 |
| 30 Sep 25 | 1,181 | 128 | 599 | 94 |
| 30 Jun 25 | 1,173 | 108 | 596 | 96 |
| 31 Mar 25 | 1,170 | -7 | 590 | 101 |
| 31 Dec 24 | 1,188 | 7 | 600 | 107 |
| 30 Sep 24 | 1,182 | -91 | 602 | 115 |
| 30 Jun 24 | 1,147 | -248 | 622 | 111 |
| 31 Mar 24 | 1,124 | -112 | 595 | 117 |
| 31 Dec 23 | 1,093 | -126 | 565 | 116 |
| 30 Sep 23 | 1,042 | -235 | 526 | 106 |
| 30 Jun 23 | 1,002 | -59 | 488 | 108 |
| 31 Mar 23 | 947 | -50 | 469 | 91 |
| 31 Dec 22 | 901 | -44 | 469 | 74 |
| 30 Sep 22 | 882 | 166 | 460 | 62 |
| 30 Jun 22 | 838 | 152 | 460 | 53 |
| 31 Mar 22 | 818 | 166 | 446 | 51 |
| 31 Dec 21 | 791 | 205 | 425 | 52 |
| 30 Sep 21 | 753 | 156 | 402 | 47 |
| 30 Jun 21 | 725 | 139 | 384 | 43 |
| 31 Mar 21 | 674 | 95 | 391 | 39 |
| 31 Dec 20 | 647 | -148 | 427 | 40 |
| 30 Sep 20 | 595 | -190 | 428 | 43 |
| 30 Jun 20 | 634 | -152 | 439 | 47 |
| 31 Mar 20 | 700 | -95 | 427 | 51 |
| 31 Dec 19 | 785 | 134 | 390 | 53 |
| 30 Sep 19 | 889 | 213 | 386 | 53 |
| 30 Jun 19 | 935 | 254 | 404 | 58 |
| 31 Mar 19 | 988 | 248 | 449 | 63 |
| 31 Dec 18 | 1,005 | 275 | 478 | 67 |
| 30 Sep 18 | 1,033 | 106 | 722 | 72 |
| 30 Jun 18 | 1,064 | 67 | 760 | 79 |
| 31 Mar 18 | 1,083 | 71 | 730 | 80 |
| 31 Dec 17 | 1,093 | 58 | 707 | 89 |
| 30 Sep 17 | 1,087 | 281 | 482 | 99 |
| 30 Jun 17 | 1,080 | 81 | 434 | 104 |
| 31 Mar 17 | 1,065 | 65 | 444 | 113 |
| 31 Dec 16 | 1,058 | 35 | 456 | 119 |
| 30 Sep 16 | 1,047 | -6 | 443 | 128 |
| 30 Jun 16 | 1,028 | 191 | 440 | 137 |
| 31 Mar 16 | 1,021 | 201 | 423 | 143 |
| 31 Dec 15 | 1,014 | 228 | 408 | 132 |
| 30 Sep 15 | 1,037 | 268 | 388 | 143 |
質の高い収益: INDVには$164.0M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が30th June, 2026に影響を及ぼしています。
利益率の向上: INDVの現在の純利益率 (26.7%)は、昨年(9.2%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: INDVの収益は過去 5 年間で年間5.4%増加しました。
成長の加速: INDVの過去 1 年間の収益成長率 ( 229.6% ) は、5 年間の平均 ( 年間5.4%を上回っています。
収益対業界: INDVの過去 1 年間の収益成長率 ( 229.6% ) はPharmaceuticals業界1%を上回りました。
株主資本利益率
高いROE: INDVの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/15 10:41 |
| 終値 | 2026/09/15 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Indivior Pharmaceuticals, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |